Tagged with Specialty Pharma

UK Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can change how it is perceived. Furthermore, he comments on the uncertainty Brexit brings to the industry and how healthcare should…

Canada Still in the process of integration, Mallinckrodt is preparing to build its launch structure in Canada. With several innovative products in the pipeline, Robin Hunter, general manager of Canadian operations, highlights the company’s ambition to be a top tier innovative specialty pharma company with a specific area of focus in…

Switzerland Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma player. Mr Volle, given your background in the innovative pharma sector, what was it that attracted you to join Lupin?…

Pharma In 2008 Focus Reports interviewed Mr. Federico Seghi Recli as he prepared to transform Molteni Farmaceutici into an International specialty pharma company. Today we catch up on the progress, investments and strategic decisions which have been made since, and ask how he plans to continue his remarkable growth as well…